Dimension Therapeutics to Present at Two Upcoming Investor Conferences

CAMBRIDGE, Mass., March 01, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, liver-directed treatments for diverse rare diseases based on an adeno-associated virus (AAV) gene delivery technology, today announced that Dimension’s CEO Annalisa Jenkins, MBBS, MRCP, will present at two upcoming investor conferences:

  • Cowen and Company 36th Annual Healthcare Conference
    Monday, March 7, 2016 at 3:20 p.m. Eastern Time
    The Boston Marriott Copley Place, Boston, MA

  • 28th Annual ROTH Conference
    Monday, March 14, 2016 at 12:00 p.m. Pacific Time
    The Ritz Carlton Hotel, Dana Point, CA

Live audio webcasts of the presentations can be accessed through the Investors section of the Company's website at www.dimensiontx.com. Replays of the webcasts will be available on the Company's website for two weeks following each presentation.

About Dimension Therapeutics, Inc.

Dimension Therapeutics, Inc. (NASDAQ:DMTX) is a leader in discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver based on the most advanced, mammalian adeno-associated virus (AAV) gene delivery technology. Dimension is actively progressing its broad pipeline, which features programs addressing unmet needs for patients suffering from inherited metabolic diseases, including OTC deficiency and GSDIa, a collaboration with Bayer in hemophilia A, and a wholly owned clinical program in hemophilia B. The company targets diseases with readily identifiable patient populations, highly predictive preclinical models, and well-described, and often clinically validated, biomarkers. Founded in 2013, Dimension maintains headquarters in Cambridge, Massachusetts.

For more information, please visit www.dimensiontx.com.

Contacts Burns McClellan, on behalf of Dimension Therapeutics, Inc. Justin Jackson, 212-213-0006, ext. 327 jjackson@burnsmc.com

Source:Dimension Therapeutics